CARLSBAD, Calif., Aug. 17, 2017 /PRNewswire/ -- Ionis
Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense
therapeutics, today announced that management will present a
company overview at the following investor conferences:
- Southern California Investor Conference on Thursday, August 24, 2017 in Newport Beach, CA;
- 2017 Wells Fargo Healthcare Conference on Wednesday, September 6, 2017 in Boston, MA; and
- 15th Annual Morgan Stanley Global Healthcare
Conference on Wednesday, September 13,
2017 in New York, NY.
The above listed dates are subject to change. Details on
presentation times or changes to presentation dates can be found on
the Company's website. Please check www.ionispharma.com for the
latest information.
A live webcast of the presentations will be available on the
"Investors & Media" section of the Ionis website. The replays
will be available within 48 hours and will be archived for a
limited time.
ABOUT IONIS PHARMACEUTICALS, INC.
Ionis is the leading company in RNA-targeted drug discovery and
development focused on developing drugs for patients who have the
highest unmet medical needs, such as those patients with severe and
rare diseases. Using its proprietary antisense technology, Ionis
has created a large pipeline of first-in-class or best-in-class
drugs, with over three dozen drugs in development.
SPINRAZA® (nusinersen) has been approved in the U.S.,
Europe, Japan and Canada for the treatment of spinal muscular
atrophy (SMA). Biogen is responsible for commercializing SPINRAZA.
Drugs that have successfully completed Phase 3 studies include
inotersen (IONIS-TTRRx), an antisense drug Ionis is
developing to treat patients with TTR amyloidosis, and
volanesorsen, an antisense drug discovered by Ionis and
co-developed by Ionis and Akcea Therapeutics to treat patients with
either familial chylomicronemia syndrome or familial partial
lipodystrophy. Akcea, an affiliate of Ionis, is a biopharmaceutical
company focused on developing and commercializing drugs to treat
patients with serious cardiometabolic diseases caused by lipid
disorders. If approved, volanesorsen will be commercialized through
Ionis' affiliate, Akcea. Both inotersen and volanesorsen are
progressing toward regulatory filings for marketing authorization.
Ionis' patents provide strong and extensive protection for its
drugs and technology. Additional information about Ionis is
available at www.ionispharma.com.
IONIS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding
Ionis Pharmaceuticals' business and the therapeutic and commercial
potential of Ionis' technologies and products in development,
including SPINRAZA, inotersen and volanesorsen. Any statement
describing Ionis' goals, expectations, financial or other
projections, intentions or beliefs is a forward-looking statement
and should be considered an at-risk statement. Such statements are
subject to certain risks and uncertainties, particularly those
inherent in the process of discovering, developing and
commercializing drugs that are safe and effective for use as human
therapeutics, and in the endeavor of building a business around
such drugs. Ionis' forward-looking statements also involve
assumptions that, if they never materialize or prove correct, could
cause its results to differ materially from those expressed or
implied by such forward-looking statements. Although Ionis'
forward-looking statements reflect the good faith judgment of its
management, these statements are based only on facts and factors
currently known by Ionis. As a result, you are cautioned not to
rely on these forward-looking statements. These and other risks
concerning Ionis' programs are described in additional detail in
Ionis' annual report on Form 10-K for the year ended December 31, 2016, and its most recent quarterly
report on Form 10-Q, which are on file with the SEC. Copies of
these and other documents are available from the Company.
In this press release, unless the context requires otherwise,
"Ionis," "Company," "we," "our," and "us" refers to Ionis
Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals,
Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals,
Inc. SPINRAZA® is a registered trademark of Biogen.
View original content with
multimedia:http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-to-present-at-upcoming-investor-conferences-300505642.html
SOURCE Ionis Pharmaceuticals, Inc.